Project Grant R21AG085439
- The National Institute on Aging (NIA) awarded a $499,996 Project Grant under the Aging Research federal grant program (CFDA 93.866) to Beaver Health, Inc., a minority-owned, woman-owned small business, to develop a prototype of the COMPASS conversational AI assistant. COMPASS is designed to provide personalized, culturally responsive support and coordination for Alzheimer's disease and related dementia (ADRD) caregivers in real-time. The 12-month project aims to develop and test the initial...
- This $114,498 Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) will fund a study to investigate the construct validity of smartwatch-derived metrics for early detection of Alzheimer's disease and related dementias. The study will recruit a diverse sample of 90 participants aged 55 and older with healthy cognition or mild cognitive impairment from the Philadelphia region. Participants will wear a Garmin Vivosmart 4 smartwatch for 30 days to passively monitor...
- The Department of Health and Human Services' National Institute on Aging provided $2,340,878 under its Aging Research program (CFDA 93.866) to assess the long-term impact of expanded telemedicine use on dementia care. The Regents of the University of California, San Francisco will conduct a sequential mixed-methods study from 2022-2025 to characterize dementia patients' telemedicine use in Kaiser Permanente Northern California and UCSF Health primary care settings. The study will analyze...
- The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), has awarded a $499,651 project grant to Carevirtue Technologies, Inc. to develop a novel, AI-enabled dementia care agent. This agent will provide 24/7 personalized education and support services to rural caregivers of individuals with Alzheimer's disease and related dementias (ADRD). The goal is to address the higher caregiving burden and lower social support experienced by rural ADRD care...
- This federal Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) provides $349,333 to Rendever, Inc. to develop and test the feasibility of a new virtual reality (VR) platform for dementia caregivers. The VR-CARES initiative aims to create a novel support system that enables in-home caregivers to connect virtually, participate in support groups, access training, and engage in shared experiences with their care recipients using...
- The National Institute on Aging (NIA) awarded Hido Technologies, Inc. a $1,240,765 Project Grant (CFDA 93.866 - Aging Research) to develop an internet-connected, self-medicating device with video direct observed therapy (VDOT) capabilities. The goal is to improve medication adherence and cognitive outcomes for persons with Alzheimer's disease and related dementias (AD/ADRD), while also reducing caregiver burden and healthcare costs. The device, called Homecare, integrates with a novel pharmacy...
- This Project Grant award from the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866) aims to develop, evaluate, and implement virtual reality (VR)-based cognitive stimulation games to enhance attention and prevent delirium in older surgical patients with cognitive impairment. The $242,840 award, effective September 2, 2025, will support a 5-year randomized controlled pilot trial led by Dr. Hina Faisal, an Assistant Professor at the Houston Methodist...
- The National Institute on Aging (NIA), part of the U.S. Department of Health and Human Services, awarded a $474,092 Project Grant under the Aging Research federal grant program (CFDA 93.866) to One Health Studio LLC in San Francisco, CA. The grant supports the development and evaluation of the "FLOURISH ALL" platform, an AI-enabled digital health solution aimed at reducing Alzheimer's disease and related dementia (ADRD) risk in midlife women through stress management and promotion of...
- This Project Grant award from the Agency for Healthcare Research and Quality (AHRQ) under the federal Research on Healthcare Costs, Quality and Outcomes (CFDA 93.226) program aims to improve long-term care (LTC) quality and safety for individuals living with dementia. With $449,999 in funding, the 3-year project starting September 2024 will implement and evaluate two decision support technology (DS tech) prototypes focused on fall prevention and staff burnout detection in LTC facilities. The...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $467,538 to Oscilloscape, Inc. (dba Oscillo Biosciences) to develop and test an innovative, wearable digital health device called "SYNG" to help aging adults with Alzheimer's disease and mild cognitive impairment. The device aims to deliver a digital therapy using music and synchronized visual brain stimulation to restore healthy brain rhythms through neural entrainment. Key outcomes...
VOICE ASSISTANT TO PROVIDE COGNITIVE STIMULATION THERAPY AT SCALE - PROJECT SUMMARY COGNITIVE STIMULATION THERAPY (CST) IS ONE OF THE MOST EFFECTIVE INTERVENTIONS FOR MAINTAINING COGNITIVE FUNCTIONING AND WELLBEING OF PERSONS LIVING WITH DEMENTIA (PLWDS). CST IS CURRENTLY RECOMMENDED BY THE UNITED KINGDOM GOVERNMENT FOR THE MANAGEMENT AND SUPPORT OF PLWDS. ALZHEIMER'S DISEASE INTERNATIONAL (ADI) ALSO RECOMMENDS CST AS AN EFFECTIVE INTERVENTION. HOWEVER, PROVIDING CST TO INDIVIDUALS IN NEED REMAINS A SERIOUS CHALLENGE. CST IS TRADITIONALLY PROVIDED BY TRAINED HEALTH PROFESSIONALS, WHICH IS COSTLY AND NOT SCALABLE. RECENT WORK HAS FOCUSED ON ADAPTING CST TO BE PROVIDED BY CARE PARTNERS AT HOME. HOWEVER, CURRENT APPROACHES ADD CONSIDERABLE BURDEN ON CARE PARTNERS, WHICH RESULTS IN LOW ADHERENCE AND ENGAGEMENT. SUCH ADHERENCE AND ENGAGEMENT ISSUES UNDERMINE THE EFFICACY OF CST AND CONSEQUENTLY, LEAD TO NON-OPTIMAL OUTCOMES. AS SUCH, IRRESPECTIVE OF THE ESTABLISHED EVIDENCE IN FAVOR OF CST, THERE REMAINS CONSIDERABLE CHALLENGES IN DISSEMINATING IT AT SCALE, SPECIFICALLY WHEN IT COMES TO INDIVIDUALS LIVING IN REMOTE LOCATIONS. WE ARGUE THAT VOICE ASSISTANTS (VAS) PROVIDE AN IDEAL PLATFORM TO DELIVER CST AT SCALE. VAS ARE WIDELY AVAILABLE GIVEN THEIR INTEGRATION WITH MOST RECENT CONSUMER DEVICES. RECENT VAS CAN SUPPORT VISUAL DISPLAYS AND VOICE INTERACTIONS - BEST OF BOTH WORLDS WHEN IT COMES TO DESIGNING SIMPLE, INTUITIVE, AND EFFECTIVE INTERFACES. MORE IMPORTANTLY, SIGNIFICANT NUMBERS OF OLDER ADULTS ACTIVELY USE VAS. THE HIGH ADOPTION AND ACCEPTANCE OF VAS AMONG OLDER ADULTS PROVIDES A UNIQUE OPPORTUNITY TO SUPPORT PLWDS AND THEIR CARE PARTNERS. THIS PROJECT AIMS TO ADVANCE THIS VISION OF LEVERAGING VAS FOR DEMENTIA CARE SUPPORT. WE WILL DEVELOP A VA TO DELIVER CUSTOMIZED AND TAILORED COGNITIVE STIMULATION THERAPY FOR PLWDS. WE WILL MINIMIZE CARE PARTNER BURDEN AND PROVIDE EFFECTIVE SUPPORT TO DELIVER CST SESSIONS AT HOME. WE WILL FOLLOW THE CENTER FOR EHEALTH RESEARCH (CEHRES) ROADMAP TO DEVELOP THE VA, WHICH WILL RESULT IN AN ITERATIVE AND COMMUNITY-DRIVEN IMPLEMENTATION PROCESS. WE WILL ALSO DEPLOY THE VA WITH 15 DYADS (PLWDS AND CARE PARTNERS) FOR 12 WEEKS. THIS WILL ALLOW US TO COLLECT GRANULAR INTERACTION, USABILITY, AND ACCEPTANCE DATA FROM REAL-WORLD SETTINGS. WE WILL ALSO CONDUCT FOCUS GROUP INTERVIEWS TO COLLECT IN-DEPTH QUALITATIVE DATA. THIS PROJECT WILL ESTABLISH A PRELIMINARY EVIDENCE BASE REGARDING THE FEASIBILITY AND ACCEPTABILITY OF USING VAS FOR DEMENTIA INTERVENTIONS. GIVEN THE WIDE ADOPTION OF VAS, THE PROJECT CAN POSITIVELY IMPACT A LARGE POPULATION OF PLWDS AND CARE PARTNERS INCLUDING THOSE LIVING IN REMOTE AND RURAL AREAS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 6/25/25 | ||
| Not listed | $432.2k | 5/22/24 |